Novo Nordisk A/S
SEMAGLUTIDE FOR USE IN MEDICINE
Last updated:
Abstract:
The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis.
Status:
Application
Type:
Utility
Filling date:
13 May 2020
Issue date:
28 Oct 2021